Ampion™ reduces COVID-19 respiratory distress mortality
The final results from the Phase I trial show treatment…
The final results from the Phase I trial show treatment with Ampion™ reduced all-cause mortality by almost 80 percent in COVID-19 patients with respiratory distress.